title: Utility of the rio score and modified rio score in korean patients with multiple sclerosis.
abstract: OBJECTIVE
  Early identification of suboptimal responders to multiple sclerosis (MS) treatment is critical for optimizing therapeutic decisions. The Rio score (RS) and modified Rio score (MRS) were developed to discriminate the responses to interferon-beta (IFNB) treatment in MS patients. This study was performed to evaluate the utility of RS and MRS in daily clinical practice in Korea.
  
  
  METHODS
  This was a real-world setting, multicenter, retrospective study of MS patients treated with IFNB from 10 hospitals in Korea. We investigated whether the RS and MRS at the early stage of IFNB therapy could predict treatment responses over 3 years. Suboptimal treatment responses at 3 years were defined as the presence of clinical relapse and/or EDSS progression and/or patients who had been treated with INFB for at least for 1 year and therapy was switched due to perceived treatment failure during the 2 years of follow-up.
  
  
  RESULTS
  Seventy patients (50 females and 20 males) were enrolled; 92% (12/13) of patients with high RS and 86% (12/14) of patients with high MRS (score 2 or 3) were suboptimal responders, whereas 93% (53/57) of patients with low RS and 93% (52/56) patients with low MRS (score 0 or 1) showed optimal responses. New active lesions on MRI with clinical relapse in high RS and MRS were the most common combination in suboptimal responders.
  
  
  CONCLUSIONS
  We confirmed that RS and MRS at 6-15 months of IFNB therapy were useful for predicting poor responders over 3 years.
authors.affiliation: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea; Ewha Womans University, Graduate School of Medicine, Seoul, Korea.
authors.forename: Jae-Won
authors.initials: JW
authors.lastname: Hyun
authors.affiliation: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
authors.forename: Su-Hyun
authors.initials: SH
authors.lastname: Kim
authors.affiliation: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
authors.forename: In Hye
authors.initials: IH
authors.lastname: Jeong
authors.affiliation: Chung-Ang University, College of Medicine, Seoul, Korea.
authors.forename: Suk-Won
authors.initials: SW
authors.lastname: Ahn
authors.affiliation: Kosin University, College of Medicine, Busan, Korea.
authors.forename: So-Young
authors.initials: SY
authors.lastname: Huh
authors.affiliation: Yeungnam University, College of Medicine, Daegu, Korea.
authors.forename: Min Su
authors.initials: MS
authors.lastname: Park
authors.affiliation: Ajou University, School of Medicine, Suwon, Korea.
authors.forename: Young In
authors.initials: YI
authors.lastname: Eom
authors.affiliation: Ajou University, School of Medicine, Suwon, Korea.
authors.forename: In Soo
authors.initials: IS
authors.lastname: Joo
authors.affiliation: Ilsan Paik Hospital, Inje University, College of Medicine, Goyang, Korea.
authors.forename: Joong-Yang
authors.initials: JY
authors.lastname: Cho
authors.affiliation: Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea; Neuroscience Center, Samsung Medical Center, Seoul, Korea.
authors.forename: Eun Bin
authors.initials: EB
authors.lastname: Cho
authors.affiliation: Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea; Neuroscience Center, Samsung Medical Center, Seoul, Korea.
authors.forename: Ju-Hong
authors.initials: JH
authors.lastname: Min
authors.affiliation: Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea; Neuroscience Center, Samsung Medical Center, Seoul, Korea.
authors.forename: Byoung Joon
authors.initials: BJ
authors.lastname: Kim
authors.affiliation: Dongguk University Ilsan Hospital, Goyang, Korea.
authors.forename: Nam-Hee
authors.initials: NH
authors.lastname: Kim
authors.affiliation: Konkuk University, School of Medicine, Seoul, Korea.
authors.forename: Jeeyoung
authors.initials: J
authors.lastname: Oh
authors.affiliation: Ewha Womans University, Graduate School of Medicine, Seoul, Korea.
authors.forename: Kee Duk
authors.initials: KD
authors.lastname: Park
authors.affiliation: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
authors.forename: Ho Jin
authors.initials: HJ
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D056910:Republic of Korea; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007155:Immunologic Factors; D016899:Interferon-beta